Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.

BACKGROUND: Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine-lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive a...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: de Jager, C, Oulhaj, A, Jacoby, R, Refsum, H, Smith, A
Formáid: Journal article
Teanga:English
Foilsithe / Cruthaithe: 2012

Míreanna comhchosúla